Douglas Esq - Sarepta Therapeutics CEO Pres
| S1RP34 Stock | BRL 40.08 0.39 0.96% |
Insider
Douglas Esq is CEO Pres of Sarepta Therapeutics
| Age | 60 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1149) % which means that it has lost $0.1149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.591) %, meaning that it generated substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sangeeta Bhatia | Vertex Pharmaceuticals Incorpor | 50 | |
| Diana McKenzie | Vertex Pharmaceuticals Incorpor | 54 | |
| Lavina CFA | Moderna | N/A | |
| Margaret McGlynn | Vertex Pharmaceuticals Incorpor | 59 | |
| Nia Tatsis | Vertex Pharmaceuticals Incorpor | N/A | |
| Shannon Klinger | Moderna | 52 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| Lloyd Carney | Vertex Pharmaceuticals Incorpor | 57 | |
| Stephane Bancel | Moderna | 50 | |
| Juan Andres | Moderna | 58 | |
| Carmen Bozic | Vertex Pharmaceuticals Incorpor | N/A | |
| Jerh Collins | Moderna | N/A | |
| Mirna Vieira | Biomm SA | N/A | |
| Bruce Sachs | Vertex Pharmaceuticals Incorpor | 58 | |
| William Young | Vertex Pharmaceuticals Incorpor | 74 | |
| Amit Sachdev | Vertex Pharmaceuticals Incorpor | 50 | |
| Michael Parini | Vertex Pharmaceuticals Incorpor | 43 | |
| Ourania Tatsis | Vertex Pharmaceuticals Incorpor | 52 | |
| Alan Garber | Vertex Pharmaceuticals Incorpor | 62 | |
| Stuart BSc | Vertex Pharmaceuticals Incorpor | 57 | |
| James Mock | Moderna | 46 | |
Management Performance
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Ciambrone, Ex Operations | ||
| Dallan Murray, VP Officer | ||
| Ian Estepan, Ex CFO | ||
| Douglas Esq, CEO Pres | ||
| Alison Nasisi, Chief VP | ||
| Bilal Arif, VP Operations | ||
| Diane Berry, Sr Affairs | ||
| Ryan Brown, Gen VP | ||
| Louise RodinoKlapac, Chief VP | ||
| Mary Jenkins, Sr Relations |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 56.41 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 25.76 X | |||
| Price To Sales | 67.46 X | |||
| Revenue | 701.89 M | |||
| Gross Profit | (165.84 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Sarepta Stock
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.